Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 27

Results For "TD"

1163 News Found

Balaji Amines Q4 FY25 revenue stood at Rs. 393 Cr
News | August 08, 2024

Balaji Amines Q4 FY25 revenue stood at Rs. 393 Cr

The pharma market is showing encouraging signs of improvement, positioning us well for future growth


JB Pharma records Q1 FY25 PAT higher by 25% to Rs. 177 Cr
News | August 08, 2024

JB Pharma records Q1 FY25 PAT higher by 25% to Rs. 177 Cr

Expect the international business including CDMO business to pick-up in the second half of the financial year


Bayer Group posts 2Q 2024 sales up 3.1% at € 11.14 billion
News | August 07, 2024

Bayer Group posts 2Q 2024 sales up 3.1% at € 11.14 billion

Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings


Gland Pharma posts 16% revenue growth in Q1 FY25
News | August 07, 2024

Gland Pharma posts 16% revenue growth in Q1 FY25

The drugmaker's net profit slipped 26 per cent on-year to Rs 143.8 crore


Cupid post Q1 FY25 profit at Rs. 8.25 Cr
News | August 06, 2024

Cupid post Q1 FY25 profit at Rs. 8.25 Cr

Cupid Ltd has reported total income of Rs. 44.02 crores during the quarter ended June 30, 2024


UK Relonchem receives marketing authorization for Levonorgestrel 1.5 mg Tablets
News | August 06, 2024

UK Relonchem receives marketing authorization for Levonorgestrel 1.5 mg Tablets

Relonchem Limited has received Marketing Authorization for the product Levonorgestrel 1.5 mg Tablets from UK MHRA


Narayana Hrudayalaya posts Q1 FY25 consolidated PAT higher at Rs. 201.37 Cr
News | August 06, 2024

Narayana Hrudayalaya posts Q1 FY25 consolidated PAT higher at Rs. 201.37 Cr

Narayana Hrudayalaya has reported total income of Rs. 1364.44 crores during the period ended June 30, 2024


Vijaya Diagnostic Centre reports Q1 FY25 consolidated PAT at Rs. 31.34 Cr
News | August 06, 2024

Vijaya Diagnostic Centre reports Q1 FY25 consolidated PAT at Rs. 31.34 Cr

Vijaya Diagnostic Centre has reported total income of Rs. 159.78 crores during the quarter ended June 30, 2024


SMS Pharmaceuticals reports Q1 FY25 consolidated PAT at Rs. 16.48 Cr
News | August 06, 2024

SMS Pharmaceuticals reports Q1 FY25 consolidated PAT at Rs. 16.48 Cr

SMS Pharmaceuticals has reported total income of Rs. 165.81 crores during the quarter ended June 30, 2024


Eris Lifesciences posts Q1 FY25 at Rs. 89 Cr
News | August 03, 2024

Eris Lifesciences posts Q1 FY25 at Rs. 89 Cr

EBITDA at Rs. 250 crore, up 47% YoY, with 35% EBITDA margin